Uniqure’s FDA submission for its Huntington’s disease therapy thrown into question
In a major setback, Uniqure said that the timing of when it can file its Huntington's treatment for FDA approval "is now
UK police charge man with attempted murder over train stabbing that wounded 11 people
U.K. police have charged a 32-year-old man with attempted murder following a stabbing attack on a train that wounded 11
Stock market today: Dow, S&P 500, Nasdaq futures rise as November kicks off with earnings, AI, Fed in focus
US stock futures made gains, with Wall Street looking to maintain upward momentum.
November trading, Berkshire's cash hoard, Big Tech's ad revenue and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
Disney Destiny Arrives in Florida
Disney Cruise Line announced that the Disney Destiny, the newest ship in the fleet, arrived in Port Canaveral, marking a
Bitcoin Drop May Be Warning for Stocks: Crypto Daybook Americas
The day ahead in crypto: Nov. 3, 2025
Economic anxiety grows during shutdown and the final push to Election Day: Morning Rundown
Plus, the Trump administration's new plan for Mexican drug cartels and a "Sunday Night Football" recap.
uniQure (NASDAQ: QURE) updates on AMT-130; FDA feedback shifts, BLA timing unclear
Pre-BLA feedback says Phase I/II external-control data may not suffice as primary evidence. AMT-130 has Breakthrough (Ap
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy co